Analytical Data
-
基因名
IL-10
- Application
-
生物活性
1.The ED50 is <0.2 ng/mL as measured by MC/9 cells. 2.Immobilized human IL10 at 10 μg/mL (100 μl/well) can bind Cynomolgus IL10RA. The ED50 for this effect is 0.2189-1.732 μg/mL. 3. Immobilized Recombinant Human IL10/Interleukin-10 Protein at 2 μg/mL (100 μL/well) can bind Biotinylated Recombinant Rhesus IL10RA Protein. The ED50 for this effect is 218.9 ng/mL. Immobilized human IL10 at 10 μg/mL (100 μL/well) can bind Cynomolgus IL10RA，The ED50 for this effect is 1.732 μg/mL.
-
别名
rHuIL-10; CSIF
-
种属
Human
-
表达系统
CHO
-
标签
Tag Free
-
纯度
Greater than 95% as determined by reducing SDS-PAGE. as determined by SDS-PAGE.
-
蛋白编号
P22301
-
表达区间
S19-N178
-
蛋白长度
Full Length of Mature Protein
-
分子量
10-20 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Interleukin-10 (IL-10) is a cytokine with potent anti-inflammatory properties, playing a crucial role in modulating immune responses. Its primary function involves inhibiting the production of pro-inflammatory cytokines and promoting the differentiation of regulatory T cells. Given its therapeutic potential, research into IL-10 recombinant protein has gained significant attention, particularly concerning its application in autoimmune diseases, chronic inflammatory conditions, and various cancers. The ability of IL-10 to balance immune activity and suppress excessive inflammation makes it an attractive candidate for novel therapeutic strategies. Studies have shown that recombinant IL-10 can enhance wound healing, support tissue regeneration, and mitigate the adverse effects of inflammatory diseases. Furthermore, its potential role in immunotherapy, particularly in enhancing anti-tumor immunity, is being actively explored. Preclinical and clinical trials have demonstrated encouraging results, suggesting that IL-10 administration can lead to improved patient outcomes. However, challenges remain in optimizing dosing strategies, delivery methods, and understanding the broader implications of IL-10 interactions within the immune microenvironment. As researchers continue to unravel the complex mechanisms behind IL-10's actions, the development of IL-10-based therapies holds promise for a range of medical applications, paving the way for innovative treatment modalities in managing immune-related disorders.
